Pioderma gangrenoso ampollar como forma de presentación de leucemia mieloide agudo: informe de un caso / Acute myeloid leukemia presented in the form of bullous pyoderma gangrenosum: a case report

El pioderma gangrenoso ampollar es una variedad infrecuente de pioderma gangrenoso, que se asocia en el 50-70% de los casos con trastornos oncohematológicos. Se comunica el caso de una paciente de 59 años, que consultó por fiebre y ampollas purpúricas de rápida progresión, con compromiso cutáneo mucoso. Con sospecha de una enfermedad neutrofílica, ampollar, o infección por gérmenes oportunistas, se realizó biopsia de piel para estudio histopatológico, inmunofluorescencia directa y cultivo. Los cultivos y la inmunofluorescencia directa fueron negativos, y la anatomía patológica reveló un denso infiltrado inflamatorio con predominio neutrofílico en dermis. Ante el diagnóstico de pioderma gangrenoso ampollar, se realizó una punción-aspiración de médula ósea cuyo resultado fue compatible con leucemia mieloide aguda. Se instauró tratamiento con corticosteroides sistémicos, a pesar de lo cual la paciente evolucionó desfavorablemente y falleció a los 15 días de su ingreso hospitalario. Este caso ilustra la asociación de esta enfermedad cutánea con trastornos oncohematológicos y el mal pronóstico que esto implica a corto plazo. (AU)

Bullous pyoderma gangrenosum is an infrequent type of pyoderma gangrenosum, associated with onco hematological diseases in 50-70% of cases. We present the case of a 59-year-old patient with fever and mucocutaneous hemorrhagic bullous of rapid progression. A biopsy for histopathology, direct immunofluorescence (DIF) and skin culture was made, considering the possibility of neutrophilic dermatoses, bullous dermatosis or an opportunistic infection. The results of both the culture and the DIF were negative. The histopathological examination of the specimen revealed a dense dermal polymorphic infiltrate composed primarily of neutrophils. Considering bullous pyoderma gangrenosum as a potential diagnosis, a bone-marrow biopsy was performed. This study revealed an acute myeloid leukemia. Although systemic corticosteroid therapy was begun, the patient presented an unfavorable evolution that led to her death 15 days after her admission at the hospital. This case shows the association between bullous pyoderma gangrenosum and onco hematological diseases. In addition, it highlights the poor prognosis related to these diseases in the short term. (AU)

Endocarditis infecciosa por Rhizobium radiobacter: Reporte de un caso / Infective endocarditis by Rhizobium radiobacter: A case report

Rhizobium radiobacter es una bacteria Gram-negativa, fijadora de nitrógeno que se encuentra principalmente en el suelo. Rara vez causa infecciones en humanos. Ha sido asociada a bacteriemia secundaria a colonización de catéteres intravasculares en pacientes inmunocomprometidos. El objetivo de este trabajo es informar un caso de endocarditis infecciosa por R. radiobacter. Se trata de paciente masculino, de 47 años de edad, con diagnóstico de enfermedad renal crónica estadio 5 en tratamiento sustitutivo con hemodiálisis, quien acude a centro asistencial por presentar fiebre de dos semanas de evolución. Es hospitalizado, se toman muestras de sangre periférica para hemocultivo y se inicia antibioticoterapia empírica con cefotaxime más vancomicina. El ecocardiograma transtorácico revelo vegetación fusiforme en válvula tricúspide con regurgitación grado III-IV/IV. Al séptimo día del inicio de la antibioterapia el paciente presenta mejoría clínica y paraclínica. La bacteria identificada por hemocultivo es Rhizobium radiobacter resistente a ceftriaxona y sensible a imipenem, amikacina, ampicilina y ampicilina/sulbactam. Debido a la mejoría clínica se decide continuar tratamiento con vancomicina y se anexa imipenem. A los 14 días de iniciada la antibioterapia el paciente es dado de alta con tratamiento ambulatorio con imipenen hasta cumplir seis semanas de tratamiento. En el ecocardiograma control se evidencio ausencia de la vegetación en la válvula tricúspide. Este caso sugiere que R. radiobacter puede ser una causa de endocarditis en pacientes portadores de catéteres intravasculares.

Rhizobium radiobacter is a Gram-negative, nitrogen-fixing bacterium, which is found mainly on the ground. It rarely causes infections in humans. It has been associated with bacteremia, secondary to colonization of intravascular catheters, in immunocompromised patients. The aim of this paper was to report the case of an infective endocarditis caused by R. radiobacter, in a 47-year-old male, diagnosed with chronic kidney disease stage 5, on replacement therapy with hemodialysis and who attended the medical center with fever of two weeks duration. The patient was hospitalized and samples of peripheral blood were taken for culture. Empirical antibiotic therapy was started with cefotaxime plus vancomycin. The transthoracic echocardiogram revealed fusiform vegetation on the tricuspid valve, with grade III-IV/IV regurgitation. On the seventh day after the start of antibiotic therapy, the patient had a clinical and paraclinical improvement. The bacterium identified by blood culture was Rhizobium radiobacter, ceftriaxone-resistant and sensitive to imipenem, amikacin, ampicillin and ampicillin/ sulbactam. Because of the clinical improvement, it was decided to continue treatment with vancomycin and additionally, with imipenem. At 14 days after the start of antibiotic therapy, the patient was discharged with outpatient treatment with imipenem up to six weeks of treatment. The control echocardiogram showed the absence of vegetation on the tricuspid valve. This case suggests that R. radiobacter can cause endocarditis in patients with intravascular catheters.

Carbapenem stewardship: positive impact on hospital ecology

INTRODUCTION: Excessive group 2 carbapenem use may result in decreased bacterial susceptibility. OBJECTIVE: We evaluated the impact of a carbapenem stewardship program, restricting imipenem and meropenem use. METHODS: Ertapenem was mandated for ESBL-producing Enterobacteriaceae infections in the absence of non-fermenting Gram-negative bacilli (GNB) from April 2006 to March 2008. Group 2 carbapenems were restricted for use against GNB infections susceptible only to carbapenems and suspected GNB infections in unstable patients. Cumulative susceptibility tests were done for nosocomial pathogens before and after restriction using Clinical and Laboratory Standards Institute (CLSI) guide-lines.Vitek System or conventional identification methods were performed and susceptibility testing done by disk diffusion according to CLSI.Antibiotic consumption (t-test) and susceptibilities (McNemar's test) were determined. RESULTS: The defined daily doses (DDD) of group 2 carbapenems declined from 61.1 to 48.7 DDD/1,000 patient-days two years after ertapenem introduction (p = 0.027). Mean ertapenem consumption after restriction was 31.5 DDD/1,000 patient-days. Following ertapenem introduction no significant susceptibility changes were noticed among Gram-positive cocci. The most prevalent GNB were P. aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp. There was no change in P. aeruginosa susceptibility to carbapenems. Significantly improved P. aeruginosa and K. pneumoniae ciprofloxacin susceptibilities were observed, perhaps due to decreased group 2 carbapenem use. K. pneumoniae susceptibility to trimethoprim-sulfamethoxazole improved. CONCLUSION: Preferential use of ertapenem resulted in reduced group 2 carbapenem use, with a positive impact on P. aeruginosa and K. pneumoniae susceptibility.

Prevalência de resistência bacteriana nas infecções de ferida operatória em cirurgia arterial periférica / Prevalence of bacterial resistance in surgical wound infections in peripheral arterial surgery

CONTEXTO: A infecção de sítio cirúrgico é uma complicação grave da cirurgia vascular periférica. O recente aparecimento de microorganismos resistentes e agressivos gera uma nova preocupação com relação ao manejo dessas infecções. OBJETIVO: Verificar a prevalência de resistência bacteriana, a epidemiologia, os possíveis fatores associados e o padrão de resistência nas infecções de ferida operatória das cirurgias arteriais periféricas. MÉTODOS: Estudo de prevalência, envolvendo 40 pacientes portadores de infecção da ferida operatória e submetidos à cirurgia de revascularização arterial periférica no período de janeiro de 2007 a maio de 2008. RESULTADOS: Participaram do estudo pacientes com média de idade de 64,2 anos, predominantemente do sexo masculino (70%). A prevalência geral de resistência bacteriana foi 72,5%, e de multirresistência, 60%. O microorganismo mais freqüentemente isolado foi o Staphylococcus aureus (40%), sendo 11 das 16 culturas (68,7%) resistentes à oxacilina. As taxas de resistência aos principais antimicrobianos testados foram: ampicilina, 85,7%; cefalosporina, 76,9%; oxacilina, 65%; e ciprofloxacina, 62,5%. Não foi identificada resistência à vancomicina e ao imipenem. CONCLUSÕES: Os achados deste estudo sugerem que a resistência bacteriana é um problema atual e muito prevalente nas cirurgias arteriais periféricas. O Staphylococcus aureus segue sendo o principal patógeno envolvido, demonstrando altas taxas de resistência. A vancomicina e o imipenem seguem sendo as principais opções terapêuticas para esse tipo de infecção.

BACKGROUND: Surgical wound infection is a severe complication of peripheral vascular surgery. The recent appearance of resistant and aggressive pathogens brings new concerns related to the management of these infections. OBJECTIVE: To verify the prevalence of bacterial resistance, epidemiology, possibly associated factors and resistance patterns in wound infections of peripheral arterial surgeries. METHODS: Prevalence study of 40 patients with surgical wound infections submitted to peripheral arterial revascularization procedures between January 2007 and May 2008. RESULTS: Mean age was 64.2 years, males represented 70% of all cases. The overall prevalence of bacterial resistance was 72.5% and multiresistance 60%. The commonest single cultured microorganism was the Staphylococcus aureus (40%), and 11 of 16 cultures (68.7%) were oxacillin-resistant. Prevalence of resistance to the main tested antibiotics: ampicillin 85.7%; cephalosporin 76.9%; oxacillin 65%; and ciprofloxacin 62.5%. Resistance to vancomycin and imipenem was not identified. CONCLUSIONS: The findings of this study suggest that bacterial resistance is a prevalent and current problem in peripheral vascular surgeries. Staphylococcus aureus is still the most frequently involved pathogen, showing high resistance rates. Vancomycin and imipenem are still the best therapeutic options to treat these infections.

Actinomicetoma por Nocardia sp: informe de cinco casos tratados con imipenem solo o combinado con amikacina / Actinomycetoma and Nocardia sp: report of five cases treated with imipenem or imipenem plus amikacin

Antecedentes: El tratamiento estándar del actinomicetoma es dapsona con trimetoprim/sulfametoxazol. En casos seleccionados amikacina, estreptomicina, kanamicina, amoxicilina/ácido clavulánico o fosfomicina. El imipenem ha mostrado tener actividad in vitro e in vivo contra algunos actinomicetos; tiene un efecto sinérgico combinado con amikacina. Objetivos: Comunicar la respuesta al tratamiento con imipenem solo o combinado con amikacina en micetomas por Nocardia sp graves o multirresistentes. Material y métodos: Presentamos cinco pacientes con actinomicetoma que habían recibido múltiples tratamientos. Se hospitalizaron tres semanas para recibir imipenem (500 mg cada ocho horas) intravenoso por vía periférica por 21 días. En dos casos se combinó con amikacina. Resultados: Tres pacientes fueron hombres y dos mujeres. En tres casos la localización fue en el dorso, uno de ellos con afección ósea y pulmonar; en un caso hubo afección de la pared abdominal y en otro en la región cervical posterior. La evolución promedio fue de 7.4 años. En dos casos se logró curación clínica y bacteriológica a un año de seguimiento. En el paciente con afección pulmonar también hubo mejoría radiográfica. En el resto de los casos se logró cierre de la mayoría de las fístulas y una disminución importante de la inflamación, aunque hubo presencia de granos con cultivo negativo. Ningún tratamiento provocó efectos colaterales. Conclusiones: El imipenem es un antibiótico de amplio espectro y consideramos que es una buena alternativa para tratar actinomicetomas graves, resistentes al tratamiento habitual o con complicaciones viscerales.

INTRODUCTION: Dapsone with trimethoprim-sulfamethoxazol is currently the standard treatment for actinomycetoma. In select cases, amikacin, streptomycin, kanamycin, amoxicillin/clavulanic acid or phosphomycin may be also added. Imipenem has shown to be effective both in vitro and in vivo against some actinomycetes. Amikacin with Imipenem has a synergistic effect. OBJECTIVES: To report our preliminary findings using imipenem alone or with amikacin for severe or multi-resistant mycetomas due to Nocardia sp. MATERIAL AND METHODS: We present 5 cases of chronic mycetoma infection previously treated with anti-bacterial multidrug regimens. All patients were hospitalized and treated with imipenem 500 mg IV, three times a day for three weeks. Three patients received in addition amikacin. RESULTS: We included 3 male and 2 female patients. The average length of disease duration was 7.4 years. In 3 cases mycetoma was located on the back; one of them involved the rib and the lung. One case was localized in the abdominal wall, and another one involved the posterior side of the cervical region. Two patients achieved clinical and bacteriological cure one year after treatment with Imipenem, and the remaining three displayed clinical improvement, even though grains were observed, cultures where negative. None of the 5 patients studied showed clinical evidence of adverse reactions to Imipenem. CONCLUSIONS: Imipenem is a strong antibiotic and constitutes an important treatment alternative for severe or multi-resistant mycetoma especially for cases with bone and visceral involvement.

Aspectos farmacológicos de meropenem / Pharmacological topics of meropenem

Meropenem is more stable than imipenem to renal dehydropeptidase I and can be used as a monodrug. It is bactericidal against most grampositive and gramnegative, aerobic and anaerobic species. Compared to imipenem, meropenem is more active against pseudomonas aeuginosa, burkholderia cepacia and some multiresistant nosocomial gramnegative strains because it is less inductor of extended spectrum B lactamases but may favor resistance against other antibiotic groups by an efflux pump induction. Its systemicdistribution in the extracellular space includes the central nervous system and is most excreted by glomerular filtration. As meropenem is more soluble than imipenem, it can be administered in bolus. Security profile: it rarely causes seizures, a frecuent effect observed with imipenem during tratment of bacterial meningitis in children. Other adverse reactions (local pain, pruritus and diarrhea) are as frecuent as described with imipenem

Neonatal Klebsiella pneumonia sepsis and imipenem/cilastatin.

Efficacy and safety of imipenem/cilastatin in neonatal Klebsiella pneumonia sepsis was investigated in 45 infants compared to 39 control infants on conventional antibiotic regimen. Sensitivity to imipenem was 94% followed by cephoxitin (88%), quinolons (80%), and amikacin (52%) according to susceptibility results in the study group. Treatment duration of surviving infants was 16.5 +/- 4.6 and 20.3 +/- 6.4 days in the study and control groups respectively (p < 0.05). Five infants (11%) vs 27 (69%) were unresponsive (septic deaths) to treatment in the study and control groups respectively (p < 0.001). The cure rates were 73% and 28% respectively (p < 0.001). Sequelae free discharge rates were 67% and 23% respectively (p < 0.001). The most frequent adverse effects of imipenem/cilastatin were Candida albicans superinfection (20%); Candida albicans colonisation (10%); impairment of liver and renal functions (19% and 10% respectively); seizures (5%); thrombocytosis (3%); thrombophlebitis (3%); urine discoloration (3%); and Staphylococcus epidermidis colonisation (2%). Imipenem is considered a good alternative for neonatal Klebsiella pneumonia sepsis with these results, however, one must be aware of the increased risk of Candida albicans superinfection.

Imipenem - cilastatina versus ceftazidima - amikacina para el tratamiento de pacientes neutropénicos febriles / Imipenem - cilastatine versus ceftazidime - amikacin in the treatment of febril neutropenic patients

Aim: To compare the efficacy of imipenem - cilastatine and ceftazidime - amikacin in the treatment of febril neutropenic patients. Design: Open prospective and randomized clinical study. Patients: 52 patients (26 females) aged 16 to 80 years old with 60 episodes of neutropenia were studied. They were randomly assigned to receive Imipenem - cilastatine in doses of 500 mg iv qid or the combination of ceftazidime 1 to 1.5 g iv tid and amikacin 7.5 mg/kg iv bid. Results: Global response to initial therapy was 53 percent in patients receiving imipenem - cilastatine and 37 percent in those receiving ceftazidime - amikacin (p=ns). When other antimicrobial were added, a 90 and 85 percent infection eradication success was achieved respectively. Six febrile episodes in the group receiving imipenem - cilastatine and 12 episodes in tha group receiving ceftazidime - amikacin had Gram positive cocci as the sole treatment outcome. Three patients receiving imipenem - cilastatine (10 percent) and 4 receiving ceftazidime - amikacin (13 percent) died. Superinfections and toxicity related to antibiotics were minimal in both groups. Conclusions: imipenem - cilastatine and the combination of ceftazidime with amikacin were equally effective in the treatment of febril episodes in neutropenic patients

Clinical evaluation of imipenem/cilastatin a brazilian multicenter study on intravenous administration followed by intramuscular administration in acute infections

E apresentado estudo multicentrico brasileiro onde foram estudados 118 pacientes portadores de infeccoes agudas diversas, clinicas e/ou cirurgicas. A terapeutica antibiotica unica utilizada, associada ou nao a remocao do foco infeccioso, foi o imipenem/cilastatina sob duas vias de administracao. Na via endovenosa foram aplicadas doses de 500mg a cada oito horas ate a melhora clinica inicial do paciente, passando, entao, para a via intramuscular com 500mg a cada 12 horas. O periodo de aplicacao foi ate a cura clinica ou incapacidade de controle clinico de infeccao. Os resultados mostraram necessidade de aplicacao da via endovenosa por tres dias e de igual tempo para a via intramuscular no controle de 89,0 por cento dos casos. Concluem que a associacao da via endovenosa a intramuscular traz vantagens do manuseio do paciente sem comprometer a eficacia medicamentosa do antibiotico.

In vitro evaluation of newer beta-lactam antibiotics against gram negative bacilli isolated from neutropenic patients.

The in-vitro susceptibility pattern to newer beta lactams namely Ticer/Clav, Azlocillin, Piperacillin and Imipenem was determined with 50 clinical strains isolated from neutropenic patients with strains isolated from neutropenic patients with sepsis, with an objective of evolving a strategy for empirical antibiotic therapy for febrile neutropenic patients. The MIC90 value for Imipenem for the Gram negative bacilli tested, other than Pseudomonas was < 0.25 mcg/ml therapy revealing a high degree of susceptibility, while for Ps. aeruginosa and related species MIC50 and MIV90 values were 2.0 and 64.0 micrograms/ml respectively. A comparatively lower degree of susceptibility was found among Gram negative bacilli included in the study to ticar/clavu, azlocillin and piperacillin indicating a moderate degree of resistance to these antibiotics. The data from this study suggests that (i) Ureidopenicillins with an aminoglycoside should be effective therapy for proven Pseudomonas and other Gram negative sepsis in febrile neutropenic patients. (ii) Imipenem would be the antibiotic of choice in Gram negative bacterial sepsis in febrile neutropenic patients where the organism is resistant to cephalosporins and ureidopenicillins.

Comparaçäo entre esquemas antibióticos com Imipenem/Cilastatina e Cefalosporinas de 3o. geraçäo no tratamento de pneumonias em pacientes com fatores de risco / Comparison between Imipenem/Cilastatin and third generation Cephalosporins in the treatment of pneumonia in patients with risk factors

Trinta e cinco episódios de pneumonia em 33 pacientes foram tratados com dois esquemas antibióticos: no grupo A foi utilizado Imipenem e no B uma cefalosporina de 3ª geraçäo; de acordo com dados bacteriológicos e/ou clínicos foram acrescentados outros antibióticos (vancomicina e aminoglicosídeo, principalmente). Todos os pacientes apresentavam fator de risco (em 16 vezes, mais de um fator) e a pneumonia foi adquirida no hospsital 20 vezes. Bactérias foram isoladas em 27 episódios: por aspirado transtraqueal em 18, hemocultura em dois, líquido pleural e um e escarro selecionado em seis. Ocorreram oito óbitos, dos quais seis no grupo B e dois no grupo A; excluindo-se os episódios por S. aureus, a mortalidade foi quatro e zero, respectivamente (p = 0,06 - teste de Fisher). A comparaçäo entre os óbitos e os que evoluíram favoravelmente mostra que as condiçöes de base tiveram provavelmente maior influência que o esquema antibiótico usado. Para conclusöes definitivas sobre a superioridade de um esquema sobre o outro é necessário aumentar a amostra, entretanto, é provável que o impemen, por seu espectro mais amplo, seja superior

Imipenem/cilastatina no tratamento de infecçöes pélvicas / Imipenem/cilastatin in the treatment of pelvic infections

Em ensaio clínico aberto, comparativo, foram estudados 21 pacientes portadoras de infecçöes pélvicas moderadas e graves, compreendendo os seguintes diagnósticos: doença inflamatória pélvica (N = 15), endometrite puerperal (N = 3) e abortamento infectado (N = 3). Após diagnóstico clínico (exame físico completo, exame ginecológico, incluindo especular, toque vaginal e toque retal) e coleta de exames laboratoriais (hemograma completo, uréia, creatina, transaminases, urina tipo I + SQ) e bacteriológicos (culturas de urina, culturas de secreçäo do colo uterino e/ou foco suspeito de infecçäo em meios para aeróbios e anaeróbios), as pacientes eram aleatória e consecutivamente alocadas em grupos I e II. O grupo I recebeu imipenem/cilastatina 500mg, a cada seis horas, por cinco a 14 dias e o grupo II recebeu ceftriaxona 1,0g a cada 24 horas pelo mesmo período. Reavaliaçäo clínica ocorreu diariamente durante a internaçäo e 15 dias após a alta. Os exames laboratoriais e bacteriológicos foram colhidos antes do início do tratamento e três a cinco dias após o término do mesmo. A idade média no grupo I foi de 27 anos e no grupo II 28,4 anos. Os agentes etiológicos mais freqüentes foram Staphylococcus sp (36,4%), E. coli (27,3%), Neisseria gonorrhoeae (13,6%), Enterococcus sp (9,1%), Streptococcus sp (9,1%) e Klebsiella sp (4,6%). Todos os casos apresentam boa evoluçäo clínica, com remissäo completa dos sinais e sintomas. O índice de cura no grupo I foi de 100% e no grupo II 90%. Todas as pacientes toleraram o tratamento de forma excelente no grupo I, sendo que no grupo II foi necessário descontinuar o tratamento em uma paciente que apresentou "rash cutâneo". O presente estudo confirma a alta eficácia e boa tolerabilidade de imipenem/cilastatina no tratamento de infecçöes pélvicas